Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany states his opinions on CAR T-cell therapies for the treatment of acute lymphocytic leukemia (ALL) and the difficulties associated with this treatment in the present day.
Challenges for access to CAR T-cell therapy
